Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate at Two Upcoming Investor Conferences

Tuesday, May 7, 2024 1 min read
Key Takeaway: Altimmune, Inc. announced its participation in two upcoming investor conferences, which reflects its engagement with the investment community. The JMP Life Sciences Conference will occur on May 14, 2024, followed by the UBS Obesity Therapeutics Day on May 23, 2024. The events will include fireside chats and are expected to be accessible through webinars, providing a platform for the company's management to discuss its developments and initiatives in peptide-based therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune's participation highlights investor interest and engagement.
  • The company is actively showcasing its innovative pipeline.
  • Upcoming events may attract potential investors and partnerships.

Full Press Release Details

GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
JMP Life Sciences Conference (New York, NY)
Tuesday, May 14, 2024
Fireside Chat at 9:00 a.m. Eastern Time
UBS Obesity Therapeutics Day (Virtual Conference)
Thursday, May 23, 2024
Fireside Chat at 10:00 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Chief Financial Officer
jweilman@burnsmc.com
Danielle.cantey@inizioevoke.com

Frequently Asked Questions

When will Altimmune participate in the JMP Life Sciences Conference?

Altimmune will participate in the JMP Life Sciences Conference on May 14, 2024.

What time is Altimmune's fireside chat on May 14?

The fireside chat on May 14 is scheduled for 9:00 a.m. Eastern Time.

When is the UBS Obesity Therapeutics Day conference?

The UBS Obesity Therapeutics Day will take place on May 23, 2024.

What is Altimmune's focus in biopharmaceuticals?

Altimmune focuses on developing innovative peptide-based therapeutics.

What therapeutic is Altimmune developing for obesity?

Altimmune is developing pemvidutide, a dual receptor agonist for obesity.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune investor conferences pemvidutide biopharmaceuticals GLP-1
Last updated: May 7, 2024